Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero(R) to help protect US adolescents and young adults

June 17, 2014 5:17 AM

5 0

(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero(R) to help protect US adolescents and young adults . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

- Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US[1]

Read more

To category page

Loading...